The WACC of Central Pharmaceutical CPC1 JSC (DP1.VN) is 9.2%.
| Range | Selected | |
| Cost of equity | 9.80% - 12.50% | 11.15% |
| Tax rate | 21.00% - 21.40% | 21.20% |
| Cost of debt | 5.20% - 7.00% | 6.10% |
| WACC | 8.1% - 10.4% | 9.2% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.75 | 0.83 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 9.80% | 12.50% |
| Tax rate | 21.00% | 21.40% |
| Debt/Equity ratio | 0.44 | 0.44 |
| Cost of debt | 5.20% | 7.00% |
| After-tax WACC | 8.1% | 10.4% |
| Selected WACC | 9.2% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for DP1.VN:
cost_of_equity (11.15%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.75) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.